Comparative Pharmacology
Head-to-head clinical analysis: CELLCEPT versus MYCOPHENOLATE MOFETIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELLCEPT versus MYCOPHENOLATE MOFETIL HYDROCHLORIDE.
CELLCEPT vs MYCOPHENOLATE MOFETIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
Mycophenolate mofetil hydrochloride is a prodrug of mycophenolic acid (MPA), a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for de novo guanosine nucleotide synthesis in T and B lymphocytes, leading to inhibition of lymphocyte proliferation and antibody production.
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
Oral: 1-1.5 g twice daily; intravenous: 1 g over 2 hours twice daily.
None Documented
None Documented
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
The terminal elimination half-life of MPA is approximately 17.9 hours (range 11.7–30.9 hours) in healthy volunteers. In renal transplant patients, half-life may be prolonged to 16.6 ± 6.2 hours. This supports twice-daily dosing with monitoring of trough levels for efficacy and toxicity.
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
Mycophenolic acid (MPA), the active metabolite, is primarily excreted in urine as the glucuronide conjugate (MPAG). Approximately 87% of an administered dose is recovered in urine, with <1% as unchanged MPA. Fecal excretion accounts for about 6% of the dose, mainly as MPAG via biliary secretion.
Category C
Category D/X
Immunosuppressant
Immunosuppressant